Overview of the [corrected] travoprost /timolol BAK-free fixed combination.

Abstract:

INTRODUCTION:Glaucoma is the second leading cause of blindness globally, representing a significant public health concern. More than 60 million people are affected by glaucoma worldwide; as this population ages, the number is expected to increase. Glaucoma is a collection of heterogeneous diseases sharing common clinical characteristics. The goal of treatment is to prevent significant visual dysfunction through reduction of intraocular pressure (IOP). AREAS COVERED:This is a review of the current literature about combination therapeutic regimens for the reduction of IOP, focusing on the risk : benefit profile of a fixed-combination therapy using travoprost and timolol. EXPERT OPINION:Since the debut of prostaglandin analogues in the 1990s, only modest innovation has occurred in glaucoma pharmacology. A growing body of research has established that the preservative benzalkonium chloride (BAK) might not be the benign contributor expected of excipient ingredients. Thus, BAK-free treatments were developed, with the goal of IOP reduction without furthering ocular surface disease symptoms. The BAK-free travoprost/timolol combination represents an important addition to glaucoma medication options and may fill an unmet need in this therapeutic arena.

authors

Konstas AG,Quaranta L,Realini T

doi

10.1517/14656566.2012.662485

subject

Has Abstract

pub_date

2012-04-01 00:00:00

pages

757-66

issue

5

eissn

1465-6566

issn

1744-7666

journal_volume

13

pub_type

杂志文章,评审
  • Current trends in antithyroid drug treatment of Graves' disease.

    abstract:INTRODUCTION:Graves' hyperthyroidism is associated with significant morbidity and mortality risk. The thionamides, methimazole, its pro-drug derivative carbimazole, and propylthiouracil, remain a cornerstone of management. Yet despite decades of use, optimal strategies for maximising treatment response and curtailing a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1232388

    authors: Okosieme OE,Lazarus JH

    更新日期:2016-10-01 00:00:00

  • Pharmacological management of human respiratory syncytial virus infection.

    abstract:INTRODUCTION:Human respiratory syncytial virus (hRSV) is the primary viral cause of respiratory diseases, leading to bronchiolitis and pneumonia in vulnerable populations. The only current treatment against this virus is palliative, and no efficient and specific vaccine against this pathogen is available. AREAS COVERE...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1806821

    authors: Kalergis AM,Soto JA,Gálvez NMS,Andrade CA,Fernandez A,Bohmwald K,Bueno SM

    更新日期:2020-12-01 00:00:00

  • The role of infectious agents in pulmonary and systemic vascular disease.

    abstract::With emphasis on the pulmonary circulation, three general types of vascular disease are discussed: fibroproliferative (atherosclerosis), cellular proliferative (endothelial neoplasms) and inflammatory (granulomatous vasculitis). The causes of these phenotypic responses are invariably multifactorial, but infectious age...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.7.1093

    authors: Egermayer P

    更新日期:2001-07-01 00:00:00

  • Needed, new paradigms in antibiotic development.

    abstract::While antibiotic resistance has grabbed the headlines and the attention of the pharmaceutical industry, the lack of susceptibility of biofilms formed both on animate and inanimate surfaces deserve greater attention from the industry, medical practitioners and regulators. The current literature tells us that the inhere...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656561003724747

    authors: Ceri H,Olson ME,Turner RJ

    更新日期:2010-06-01 00:00:00

  • Pemetrexed for the treatment of non-small cell lung cancer.

    abstract:INTRODUCTION:Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have become available for the treatment of this disease. Pemetrexed , a multi-target folate antagonist, has improved the survival of non-squamous...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.802774

    authors: Genova C,Rijavec E,Truini A,Coco S,Sini C,Barletta G,Dal Bello MG,Alama A,Savarino G,Pronzato P,Boccardo F,Grossi F

    更新日期:2013-08-01 00:00:00

  • Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis.

    abstract:INTRODUCTION:Clostridium difficile has become the most important healthcare-associated infection worldwide within the past decade. This is in part due to the emergence of a highly virulent epidemic strain of C. difficile as well as the relative ineffectiveness of current therapies at producing a sustained response. Fid...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.802307

    authors: Hostler CJ,Chen LF

    更新日期:2013-08-01 00:00:00

  • Metabolic syndrome management.

    abstract::Overweight, obesity and the metabolic syndrome occur in genetically susceptible individuals with environmental influences, and may be further compounded by other disorders of metabolism or pharmacological therapy that increase insulin resistance or promotes weight gain. Treatment of the metabolic syndrome should focus...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.13.2059

    authors: Stone NJ,Schmeltz LR

    更新日期:2007-09-01 00:00:00

  • A review of the clinical efficacy and tolerability of almotriptan in acute migraine.

    abstract::Almotriptan is a serotonin (5-hydroxytryptamine, 5HT)(1B/1D)-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.7.1157

    authors: Dodick DW

    更新日期:2003-07-01 00:00:00

  • Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.

    abstract:INTRODUCTION:Increasing population age, obesity and physical inactivity mean that type 2 diabetes mellitus (T2DM) is increasingly common. Current treatments may be limited by adverse events, drug-drug interactions or contraindication/need for dose adjustment in patients with renal impairment. AREAS COVERED:This paper ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.642863

    authors: Forst T,Pfützner A

    更新日期:2012-01-01 00:00:00

  • Dapagliflozin for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Despite the availability of many antihypreglycemic agents, many patients with type 2 diabetes (T2DM) fail to achieve the glycemic treatment goal, primarily due to progressive beta-cell dysfunction, and increased risk of hypoglycemia. AREAS COVERED:The aim of the present article is to review the efficacy a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.812632

    authors: Abdul-Ghani MA,DeFronzo RA

    更新日期:2013-08-01 00:00:00

  • Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures.

    abstract::Injectable and absorbable contrast media for the use in radiology, all of which contains iodine as an essential component, has been, and continues to be, one of the main sources of agents which cause hospital-acquired renal failure. Although numerous methods have been explored to prevent renal contrast damage, radioco...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.5.639

    authors: Mintz EP,Gruberg L

    更新日期:2003-05-01 00:00:00

  • Recent advances in the medical therapy of Crohn's disease in childhood.

    abstract::Crohn's disease (CrD) is characterised by an ongoing inflammatory response in the gut, in the absence of an obvious trigger. The treatment of CrD in children, during relapse and remission, requires special consideration of growth and development. This review addresses the use of present medical management strategies, ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.15.2553

    authors: Bremner AR,Beattie RM

    更新日期:2007-10-01 00:00:00

  • Androgen pathway resistance in prostate cancer and therapeutic implications.

    abstract:INTRODUCTION:Metastatic prostate cancer is an incurable disease that is treated with a variety of hormonal therapies targeting various nodes of the androgen receptor (AR) pathway. Invariably patients develop resistance and become castration resistant. Common treatments for castration-resistant disease include novel hor...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1055249

    authors: Maughan BL,Antonarakis ES

    更新日期:2015-01-01 00:00:00

  • Intravesical therapy for bladder cancer.

    abstract:INTRODUCTION:Transurethral resection of bladder tumor (TURBT) is the gold standard initial diagnostic intervention for bladder cancer and provides diagnostic, therapeutic and prognostic benefit in non-muscle-invasive bladder cancer (NMIBC). However, TURBT alone is inadequate for optimal management of NMIBC, as patients...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1024656

    authors: Patel SG,Cohen A,Weiner AB,Steinberg GD

    更新日期:2015-04-01 00:00:00

  • The use of cephalosporins for gonorrhea: the impending problem of resistance.

    abstract::Gonorrhea remains an important clinical and public health problem throughout the world. Gonococcal infections have historically been diagnosed by Gram stain and culture but are increasingly diagnosed through nucleic acid tests, thereby eliminating the opportunity for antimicrobial susceptibility testing. Gonococcal in...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902731993

    authors: Barry PM,Klausner JD

    更新日期:2009-03-01 00:00:00

  • Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.

    abstract:INTRODUCTION:Many patients with type 2 diabetes mellitus (T2DM) fail to achieve the desired A1c goal because the antidiabetic medications used do not correct the underlying pathophysiologic abnormalities and monotherapy is not sufficiently potent to reduce the A1c to the 6.5 - 7.0% range. Insulin resistance and islet (...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1114098

    authors: Triplitt C,Solis-Herrera C,Cersosimo E,Abdul-Ghani M,Defronzo RA

    更新日期:2015-01-01 00:00:00

  • Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.

    abstract:BACKGROUND:Alzheimer's disease is thought to be caused by increased formations of neurotoxic amyloid beta (A beta) peptides, which give rise to the hallmark amyloid plaques. Therefore, pharmacological agents that reduce A beta formation may be of therapeutic benefit. OBJECTIVE:This paper reviews the pharmacology and c...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903044982

    authors: Henley DB,May PC,Dean RA,Siemers ER

    更新日期:2009-07-01 00:00:00

  • State-of-the-art pharmacotherapy for diabetic neuropathy.

    abstract:INTRODUCTION:The global epidemic of diabetes has led to an epidemic of diabetes complications. Diabetic neuropathy is the most common microvascular complication, of which diabetic peripheral neuropathy (DPN) and autonomic neuropathy (AN) are the most prevalent, affecting ~50% of patients. DPN results in pain with a poo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1812578

    authors: Azmi S,Alam U,Burgess J,Malik RA

    更新日期:2021-01-01 00:00:00

  • Gout--what are the treatment options?

    abstract::There has been an increase in the incidence and prevalence of gout in the past several decades. A distinction needs to be made between the treatment of gout as an acute inflammatory disease and the lowering of the serum urate (SU) levels into a normal range. Treating acute gout attacks alone is not sufficient to preve...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902950742

    authors: Schlesinger N,Dalbeth N,Perez-Ruiz F

    更新日期:2009-06-01 00:00:00

  • Varicella zoster: an update on current treatment options and future perspectives.

    abstract:INTRODUCTION:Varicella zoster virus is a highly contagious virus that causes a primary infection known as varicella (chickenpox) that may reactivate years later to cause herpes zoster (HZ or shingles). After shingles heal, patients may develop post-herpetic neuralgia (PHN), neuropathic pain syndrome that can cause sign...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.860443

    authors: Kim SR,Khan F,Ramirez-Fort MK,Downing C,Tyring SK

    更新日期:2014-01-01 00:00:00

  • Pharmacotherapy for the prevention of malaria in pregnant women: currently available drugs and challenges.

    abstract:INTRODUCTION:Malaria in pregnancy continues to be a significant public health burden globally, with over 100 million women at risk each year. Sulfadoxine-pyrimethamine (SP) is the only antimalarial recommended for intermittent preventive therapy in pregnancy (IPTp) but increasing parasite resistance threatens its viabi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1526923

    authors: Moore BR,Davis TME

    更新日期:2018-11-01 00:00:00

  • New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.

    abstract:BACKGROUND:Sitagliptin is a highly selective oral dipeptidyl peptidase-4 inhibitor. This drug increases the plasma concentration of active glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide. These two hormones then simulate the secretion of insulin in a glucose-dependent manner and inhibit glu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.9.1495

    authors: Gagliardino JJ,Santoro S,Arellano S,Di Girolamo G

    更新日期:2008-06-01 00:00:00

  • Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

    abstract:INTRODUCTION:Glioblastoma multiforme (GBM) is the most common high grade primary brain tumor in adults. Despite significant advances in treatment, the prognosis remains poor. Bevacizumab (BVZ) and irinotecan (CPT-11) are currently being investigated in the treatment of GBM patients. Although treatment with BVZ and irin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.566558

    authors: Jakobsen JN,Hasselbalch B,Stockhausen MT,Lassen U,Poulsen HS

    更新日期:2011-04-01 00:00:00

  • Adjuvant medical therapy for prostate cancer.

    abstract:IMPORTANCE OF THE FIELD:Prostate cancer is a common cancer and the role of adjuvant medical therapy continues to be investigated. An understanding of the use of adjuvant medical therapy is essential for the appropriate care of prostate cancer patients, especially for those with locally advanced or high-risk disease. A...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.516252

    authors: Sumey C,Flaig TW

    更新日期:2011-01-01 00:00:00

  • Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.

    abstract:OBJECTIVE:To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chronic patients (>3 years). RESEARCH DESIGN AND METHODS:Post hoc analysis o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究

    doi:10.1080/14656566.2016.1174692

    authors: Hargarter L,Bergmans P,Cherubin P,Keim S,Conca A,Serrano-Blanco A,Bitter I,Bilanakis N,Schreiner A

    更新日期:2016-06-01 00:00:00

  • Current strategies for the treatment of complicated intraabdominal infections.

    abstract:INTRODUCTION:Complicated intraabdominal infections (cIAIs) are a common cause of infection-related morbidity and mortality in hospitalized patients and present many challenges unique from other serious infections. cIAIs are generally polymicrobial in nature; however, controversy exists around the pathogenicity of some ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.821109

    authors: Skrupky LP,Tellor BR,Mazuski JE

    更新日期:2013-10-01 00:00:00

  • Acute promyelocytic leukemia: what are the treatment options?

    abstract:IMPORTANCE OF THE FIELD:Acute promyelocytic leukemia (APL) represents a paradigm of therapeutic success in clinical hematology. Since the introduction of all-trans-retinoic-acid in the early 1980s, complete remission rates exceed 90% and the cure rate is > 70%. Notwithstanding, various questions concerning the manageme...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903505115

    authors: Ferrara F

    更新日期:2010-03-01 00:00:00

  • Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease.

    abstract:INTRODUCTION:Alzheimer's disease (AD)-related epileptic comorbidity is now well documented and appears to have been previously underestimated. Prescribing antiepileptic drugs (AEDs) in AD patients aims at preventing seizure-related morbi-mortality and the occurrence of deleterious status epilepticus. At the earlier sta...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1496237

    authors: Cretin B

    更新日期:2018-08-01 00:00:00

  • Myelofibrosis: an update on drug therapy in 2016.

    abstract:INTRODUCTION:Primary myelofibrosis (PMF) is the least common but the most aggressive of the classic Philadelphia chromosome-negative myeloproliferative neoplasms. Survival is much shorter in PMF than in polycythemia vera (PV) or essential thrombocythemia (ET). Post-PV/ET myelofibrosis (MF) is clinically indistinguishab...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1252333

    authors: Bose P,Verstovsek S

    更新日期:2016-12-01 00:00:00

  • The use of alpha-adrenoceptor antagonists in lower urinary tract disease.

    abstract::alpha-adrenoceptor antagonists have traditionally been used in the treatment of hypertension but in recent years they have become increasingly common in the treatment of benign prostatic enlargement (BPE), where they reduce the 'dynamic' component of bladder outlet obstruction and appear to have additional actions to ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.2.167

    authors: Chess-Williams R

    更新日期:2002-02-01 00:00:00